1. Reducing adverse events associated with the glucagon stimulation test for the assessment of growth hormone deficiency in adults with a high prevalence of pituitary hormone deficiencies
- Author
-
Carmela Caputo, Maresa M. Derbyshire, Katerina V Kiburg, Caroline Jung, Reetu Gogna, Balasubramanian Krishnamurthy, Margaret Zacharin, Kylie McLachlan, Nirupa Sachithanandan, Richard J MacIsaac, and Alice Hong
- Subjects
Adult ,medicine.medical_specialty ,Nausea ,Endocrinology, Diabetes and Metabolism ,030209 endocrinology & metabolism ,Gastroenterology ,Growth hormone deficiency ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,Internal medicine ,Post-hoc analysis ,Prevalence ,medicine ,Humans ,Dwarfism, Pituitary ,Adverse effect ,Retrospective Studies ,Hydrocortisone ,Human Growth Hormone ,business.industry ,Glucagon ,medicine.disease ,Growth Hormone ,030220 oncology & carcinogenesis ,Cohort ,Vomiting ,medicine.symptom ,business ,Glucocorticoid ,medicine.drug - Abstract
DESIGN A retrospective review of the adverse events (AEs) in 78 patients during the glucagon stimulation test (GST) for the assessment of growth hormone deficiency (GHD) before and after protocol amendments which aimed to reduce AEs in a group of patients with a high prevalence of pituitary hormone deficiencies. PATIENTS Based on our observations of frequent AEs during the standard GST protocol in an initial 25 patients (cohort 1), a modified protocol was introduced to include the routine administration of 20 mg of hydrocortisone pre-GST in a subsequent 53 patients (cohort 2). Post hoc analysis of the effect of glucocorticoid dosing pre-GST on AEs was examined in those receiving
- Published
- 2021
- Full Text
- View/download PDF